Flizasertib

DB21613InvestigationalSmall molecule

Flizasertib is a small molecule drug. The usage of the INN stem '-sertib' in the name indicates that Flizasertib is a serine/threonine kinase inhibitor. Flizasertib is under investigation in clinical... Flizasertib is under investigation in clinical trial NCT06602453 (A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)).

Mechanism: Pharmacologically active on Receptor-interacting serine/threonine-protein kinase 1
Curator reviewed
Formula / weight: C₁₅H₁₄FN₃O · 271.295 g/mol (avg)
Code names: GDC-8264 · RG-6287 · RO-7288817

Resolves to

Compound

UNII9HU54LL76CCAS2268739-68-8ChEMBLCHEMBL5314462ChEBI759168PubChem137408242

Structure

InChIKeyLMXPZWQVDDSYHH-RYUDHWBXSA-NSMILESF[C@H]1C[C@H](N2N=C(N=C12)C(=O)C1CC1)C1=CC=CC=C1

Targets

Q13546RIPK1

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Flizasertib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account